NCT00651729
Completed
Phase 2
Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Stroke
- Sponsor
- Allergan
- Enrollment
- 279
- Primary Endpoint
- Adverse events
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity
Investigators
Eligibility Criteria
Inclusion Criteria
- •Medically stable poststroke patients with spastic muscles in the upper limb
Exclusion Criteria
- •Stroke within 6 months of study enrollment
- •Previous therapy with Botulinum Toxin Type A for treatment of any condition prior to 4 months of enrollment, for treatment of any condition prior to 01 January 1998
Outcomes
Primary Outcomes
Adverse events
Time Frame: Week 54
Secondary Outcomes
- Spasticity as measured by the Ashworth scale(Week 54)
Similar Trials
Completed
Phase 3
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive BladderOveractive BladderNCT00311376Allergan416
Completed
Phase 3
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive BladderOveractive BladderNCT00461292Allergan275
Completed
Phase 2
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung FunctionStrokeMuscle SpasticityMotor Neuron DiseaseNCT00076687Allergan155
Terminated
Phase 2
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive BladderOveractive BladderNCT00575016Allergan74
Completed
Phase 3
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinenceOveractive BladderNCT00910845Allergan557